A research study published in the journal Neoplasia and led by principal investigator Nallasivam Palanisamy, Ph.D., associate scientist in the Vattikuti Urology Institute at Henry Ford Health System, has identified a novel prostate cancer gene fusion involving the KLK4 protein coding gene and KLKP1 pseudogene. This unique biomarker can be detected in the urine samples of patients with prostate cancer, offering a non-invasive means of detection.
Currently, the prostate specific antigen (PSA) exam is used as the standard screening method for prostate cancer. However, elevated PSA levels are not exclusive to prostate cancer, as they can also be caused by benign prostate conditions. As a result, an elevated PSA test can sometimes lead to an unnecessary prostate biopsy for the patient, which carries a risk of bleeding and infection. Findings from this research may offer a more accurate and reliable method to diagnose prostate cancer.
“This study is exciting because it has the potential to offer a non-invasive alternative to the traditional PSA test in order to diagnose significant prostate cancers,” said Craig Rogers, M.D., chair of the Vattikuti Urology Institute at Henry Ford Health System. “The discovery of new biomarkers ultimately benefits our patients, as it advances our understanding of this complex disease and how to most effectively treat it.”
When the KLK4 protein coding gene and KLKP1 pseudogene fuse together, the fusion gene KLK4-KLKP1 is formed. Pseudogenes like KLKP1 are the non-functional, or dead, versions of an actual gene that is normally not expressed in a cell but can become active in cancerous cells and disrupt the functions of the actual gene.
“The unique feature of this fusion gene is the conversion of the noncoding pseudogene KLKP1 into a protein coding gene, and its unique expression in about 30 percent of high Gleason grade prostate cancer,” said Dr. Palanisamy. “Like other ETS family gene fusions, KLK4-KLKP1 can also be detected in the urine samples of patients with prostate cancer, enabling non-invasive detection of prostate cancer. Given the unique feature of this fusion, prostate cancer specific expression, oncogenic properties and noninvasive detection, this novel gene fusion has the potential to be used as a biomarker for early detection of prostate cancer and a therapeutic target.”
The researchers conducting this study screened a cohort of 659 patients (380 Caucasian American; 250 African American, and 29 patients of other races), which revealed that the KLK4-KLKP1 fusion gene is expressed in about 32 percent of prostate cancer patients, representing a distinct subset of prostate cancer cases. Correlative analysis showed that the new fusion gene can be used in combination with other prostate cancer molecular markers for cancer detection. In addition to urine samples, the fusion could also be detected in needle biopsy tissue samples by using a specific antibody.
Prostate cancer is the most common cancer among men in the United States. Advances in diagnosis, treatment, and management have resulted in increased survival rates, yet prostate cancer still remains the second leading cause of cancer-related deaths among American men. One of the major barriers to achieving successful prostate cancer control is the underlying molecular complexity of the disease itself.
The Latest on: Prostate cancer
via Google News
The Latest on: Prostate cancer
- UCSD Researchers Find More Inclusive Genetic Tool To Predict Prostate Canceron February 23, 2021 at 11:14 am
Building upon previous research, an international team led by scientists at UC San Diego School of Medicine validated a more inclusive and comprehensive ...
- UCSD Researchers Find Genetic Tool To Predict Prostate Canceron February 23, 2021 at 10:49 am
The UCSD-led team validated a more inclusive and comprehensive genetic tool for predicting age of onset of aggressive prostate cancer.
- Genetic tool improves estimation of prostate cancer risk in diverse ethnic/racial groupson February 23, 2021 at 10:08 am
Building upon previous research, an international team led by scientists at University of California San Diego School of Medicine, has validated a more inclusive and comprehensive genetic tool for ...
- Targeting MAPK4: potential therapy for prostate canceron February 23, 2021 at 6:52 am
The battle against late-stage prostate cancer might have found a potential new strategy to combat this deadly disease. Research led by Baylor College ...
- Propella Therapeutics Partners with National Cancer Institute to Develop New Treatment for Metastatic Prostate Canceron February 23, 2021 at 5:38 am
Propella Therapeutics Inc. (Propella), a leader in the development of innovative, best-in-class prescription products, and the National ...
- Prostate Cancer Vaccines Market 2020-2027:Dendreon Corporation, Bavarian Nordic, Advantagene| Ameco Researchon February 22, 2021 at 7:18 pm
The "Prostate Cancer Vaccines Market Outlook to 2020-2027" report has been added to the Ameco Research offering. The global Prostate Cancer Vaccines market research report is the well-analyzed ...
- Targeting MAPK4 enzyme may be a potential new strategy to combat prostate canceron February 21, 2021 at 10:20 am
The battle against late-stage prostate cancer might have found a potential new strategy to combat this deadly disease.
- Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetateon February 20, 2021 at 4:00 pm
Evaluation of the comparative effectiveness of enzalutamide and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) is limited to meta-analyses of randomized trials ...
- Targeting MAPK4 emerges as a promising therapy for prostate canceron February 19, 2021 at 2:15 pm
The battle against late-stage prostate cancer might have found a potential new strategy to combat this deadly disease. Research led by Baylor College of Medicine reveals in the Journal of Clinical ...
- Modulating the unfolded protein response with ONC201 to impact on radiation response in prostate cancer cellson February 19, 2021 at 2:31 am
Prostate cancer (PCa) is the most common non-cutaneous cancer in men and a notable cause of cancer mortality when it metastasises. The unfolded protein response (UPR) can be cytoprotective but when ...
via Bing News